Bridgeway Capital Management LLC Purchases 93,488 Shares of Pediatrix Medical Group, Inc. $MD

Bridgeway Capital Management LLC raised its position in Pediatrix Medical Group, Inc. (NYSE:MD) by 14.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 740,280 shares of the company’s stock after buying an additional 93,488 shares during the period. Bridgeway Capital Management LLC’s holdings in Pediatrix Medical Group were worth $15,835,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Guggenheim Capital LLC bought a new position in Pediatrix Medical Group in the fourth quarter valued at about $747,000. AQR Capital Management LLC raised its position in Pediatrix Medical Group by 4.7% in the fourth quarter. AQR Capital Management LLC now owns 551,823 shares of the company’s stock valued at $11,803,000 after purchasing an additional 24,633 shares during the last quarter. Cetera Investment Advisers raised its position in Pediatrix Medical Group by 48.4% in the fourth quarter. Cetera Investment Advisers now owns 16,808 shares of the company’s stock valued at $360,000 after purchasing an additional 5,481 shares during the last quarter. Lazard Asset Management LLC raised its position in Pediatrix Medical Group by 34.3% in the fourth quarter. Lazard Asset Management LLC now owns 138,358 shares of the company’s stock valued at $2,959,000 after purchasing an additional 35,349 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Pediatrix Medical Group by 4.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 86,572 shares of the company’s stock valued at $1,852,000 after purchasing an additional 3,790 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Pediatrix Medical Group news, Director Shirley A. Weis sold 36,028 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.80% of the company’s stock.

Pediatrix Medical Group Trading Down 2.5%

Shares of MD stock opened at $23.56 on Thursday. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 11.44 and a beta of 0.69. The stock has a 50-day moving average of $22.58 and a 200-day moving average of $21.70. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.45. Pediatrix Medical Group, Inc. has a 1-year low of $11.84 and a 1-year high of $24.99.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. The company had revenue of $476.20 million during the quarter, compared to analysts’ expectations of $465.83 million. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.33 earnings per share. On average, equities research analysts forecast that Pediatrix Medical Group, Inc. will post 2.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

MD has been the subject of several research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Friday, March 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $27.00 target price on shares of Pediatrix Medical Group in a research report on Monday, April 20th. Deutsche Bank Aktiengesellschaft set a $19.00 price target on Pediatrix Medical Group in a research note on Friday, February 20th. UBS Group increased their price target on Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Finally, Mizuho set a $24.00 price target on Pediatrix Medical Group in a research note on Friday, May 8th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $22.50.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.